12 Consumer Discretionary Stocks Moving In Tuesday’s Intraday Session

Gainers Polished.com (AMEX:POL) stock rose 45.7% to $8.79 during Tuesday’s regular session. The company’s market cap stands at…

Gainers

  • Polished.com (AMEX:POL) stock rose 45.7% to $8.79 during Tuesday’s regular session. The company’s market cap stands at $18.5 million.
  • Dogness (Intl) (NASDAQ:DOGZ) shares increased by 28.42% to $6.54. The company’s market cap stands at $13.1 million.
  • PLBY Group (NASDAQ:PLBY) shares rose 24.0% to $1.24. The company’s market cap stands at $91.8 million.
  • Yoshiharu Global (NASDAQ:YOSH) stock increased by 22.46% to $6.65. The company’s market cap stands at $8.6 million.
  • Amesite (NASDAQ:AMST) stock moved upwards by 13.33% to $2.55. The company’s market cap stands at $6.4 million.
  • Barnes & Noble Education (NYSE:BNED) shares increased by 13.08% to $1.69. The market value of their outstanding shares is at $89.5 million.

Losers

  • Jeffs Brands (NASDAQ:JFBR) shares fell 14.4% to $2.61 during Tuesday’s regular session. The company’s market cap stands at $3.1 million.
  • Mullen Automotive (NASDAQ:MULN) shares decreased by 12.81% to $12.46. The market value of their outstanding shares is at $51.4 million.
  • Vince Holding (NYSE:VNCE) stock declined by 10.12% to $3.11. The company’s market cap stands at $38.8 million.
  • Rivian Automotive (NASDAQ:RIVN) stock decreased by 9.8% to $21.16. The market value of their outstanding shares is at $20.2 billion.
  • VinFast Auto (NASDAQ:VFS) shares declined by 9.2% to $7.6. The company’s market cap stands at $17.7 billion.
  • Lazydays Hldgs (NASDAQ:LAZY) shares declined by 9.15% to $6.41. The market value of their outstanding shares is at $89.8 million.
    See Also: www.benzinga.com/money/best-consumer-cyclical-stocks/

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Analyst Downgrades FibroGen On Questions Regarding Future Direction

Earlier today, FibroGen Inc (NASDAQ: FGEN) said its Phase 3 ZEPHYRUS-1 trial of pamrevlumab in idiopathic pulmonary fibrosis (IPF) did not meet the primary endpoint of change in forced vital capacity (FVC) from baseline at week 48 or the secondary endpoint of a decline in FVC percent 

FGEN

Read More

Nasdaq, S&P 500 Eye Rebound While Bitcoin Edges Down: Amazon’s Q3 Lifts Tech Stocks As Traders Eye Fed’s Favorite Inflation Gauge

As Amazon, Inc. (NASDAQ:AMZN) hawked good tidings, the negative sentiment in the equity market appears to have reversed. The recovery could be in part due to traders looking for bargains following a two-day slump seen in the market.

AAPL